{"id":55952,"date":"2023-04-18T16:04:18","date_gmt":"2023-04-18T14:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/"},"modified":"2023-04-18T16:04:18","modified_gmt":"2023-04-18T14:04:18","slug":"stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/","title":{"rendered":"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio"},"content":{"rendered":"
\n

BURLINGTON, Mass.–(BUSINESS WIRE)–#PCR<\/a>–Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR\u2122 platform, the naica\u00ae system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute quantitation of nucleic acids from genetic mutations found across a widespread range of oncological indications.<\/p>\n

<\/a><\/p>\n

\n\u201cThe release of these assays, in addition to our other available ready-to-use kits, is a continuation of Stilla\u2019s strategy to offer an ever-growing menu of content covering an increasing number of clinically-relevant biomarkers,\u201d says Remi Dangla, Founder and Chief Technology Officer at Stilla Technologies. \u201cBy expanding the volume of gene targets available for interrogation in patient samples using an easy-to-perform digital PCR test, we\u2019re empowering research and clinical scientists to leverage their own labs in order to get answers to their biological questions, in a matter of just a couple of hours.\u201d<\/p>\n

\nThe naica\u00ae system, the flagship digital PCR platform from Stilla Technologies, is used across a broad spectrum of applications, including oncology, cell and gene therapy, and environmental testing. The company offers off-the-shelf digital PCR kits for use on the naica\u00ae system, as well as assay development services for custom assay design.<\/p>\n

\nStilla Technologies is currently exhibiting at the Annual Meeting meeting of the American Association of Cancer Research (AACR) where the naica\u00ae system will be featured in several scientific posters, including research in collaboration with Promega Corporation, Atila Biosystems, and University of Athens. More information on Stilla product offerings and scientific posters can be obtained at Stilla\u2019s exhibition booth #3172 from our scientific specialists.<\/p>\n

\nAbout Stilla Technologies<\/b><\/p>\n

\nStilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla\u2019s groundbreaking Crystal Digital PCR\u2122 solution, the naica\u00ae system, is the industry\u2019s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA. To learn more, visit www.stillatechnologies.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact – Christopher Hynes
\n
christopher.hynes@stillatechnologies.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BURLINGTON, Mass.–(BUSINESS WIRE)–#PCR–Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR\u2122 platform, the naica\u00ae system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55952","6":"format-standard","7":"category-industry"},"yoast_head":"\nStilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BURLINGTON, Mass.–(BUSINESS WIRE)–#PCR–Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR\u2122 platform, the naica\u00ae system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T14:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230418005848\/en\/1412589\/21\/Stilla_Technologies_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio\",\"datePublished\":\"2023-04-18T14:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/\"},\"wordCount\":419,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005848\\\/en\\\/1412589\\\/21\\\/Stilla_Technologies_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/\",\"name\":\"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005848\\\/en\\\/1412589\\\/21\\\/Stilla_Technologies_Logo.jpg\",\"datePublished\":\"2023-04-18T14:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005848\\\/en\\\/1412589\\\/21\\\/Stilla_Technologies_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005848\\\/en\\\/1412589\\\/21\\\/Stilla_Technologies_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/","og_locale":"en_US","og_type":"article","og_title":"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio - Pharma Trend","og_description":"BURLINGTON, Mass.–(BUSINESS WIRE)–#PCR–Stilla Technologies today announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR\u2122 platform, the naica\u00ae system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples. Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-18T14:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230418005848\/en\/1412589\/21\/Stilla_Technologies_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio","datePublished":"2023-04-18T14:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/"},"wordCount":419,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005848\/en\/1412589\/21\/Stilla_Technologies_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/","url":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/","name":"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005848\/en\/1412589\/21\/Stilla_Technologies_Logo.jpg","datePublished":"2023-04-18T14:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230418005848\/en\/1412589\/21\/Stilla_Technologies_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230418005848\/en\/1412589\/21\/Stilla_Technologies_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/stilla-technologies-adds-20-new-oncology-liquid-biopsies-kits-to-its-reagents-portfolio-from-partner-apexbio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Stilla Technologies adds 20 new oncology liquid biopsies kits to its reagents portfolio from partner ApexBio"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55952"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55952\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}